trending Market Intelligence /marketintelligence/en/news-insights/trending/fldV79hHZ3QqUVOqLYGorg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Abbott Q3 profit rises 12% YOY; 2019 outlook revised

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Abbott Q3 profit rises 12% YOY; 2019 outlook revised

Abbott Laboratories said its third-quarter earnings grew 12% year over year and updated its outlook for 2019.

The Abbott Park, Ill.-based healthcare company reported third-quarter adjusted earnings from continuing operations of $1.51 billion, or 84 cents per share, up from $1.34 billion, or 75 cents per share, a year earlier.

The S&P Global Market Intelligence consensus normalized EPS estimate for the quarter was 84 cents.

Abbott booked net sales of $8.08 billion, a 5.5% year-over-year growth from $7.66 billion.

On a GAAP basis, Abbott said earnings from continuing operations totaled $960 million, or 53 cents per share, up from $554 million, or 31 cents per share, in 2018.

For full year 2019, the company revised its adjusted EPS from continuing operations outlook to the range of $3.23 to $3.25, from the prior guidance of between $3.21 and $3.27.

On a GAAP basis, the projected full-year EPS of Abbott was narrowed to the $2.06 to $2.08 range from its previous estimate of $2.06 to $2.12.

For the fourth quarter, Abbott is targeting adjusted EPS in the range of 94 cents to 96 cents, while GAAP EPS is anticipated to be between 59 cents and 61 cents.

The S&P Global Market Intelligence consensus normalized EPS estimates for fourth-quarter and full-year 2019 are 94 cents and $3.24, respectively.